الفهرس 
? Epidemiology and Prognostic FactorsOnly 14 pages are availabe for public view
 |  | from | 137 |  |  |
| | | from | 137 | | |
Abstract
Maximum benefit is expected with careful selection of patients; young patients, those with good initial ECOG performance status, hormone receptor positive patients, chemotherapy-naïve patients, those with relatively low disease burden, and patients with no visceral sites of involvement.
Still, further larger multi-center studies are needed for proper characterization of our population, to identify prognostic factors and determinants of survival, and to maximize treatment strategies for our patients.
this retrospective analysis we are aiming at evaluating the efficacy; response rate (RR), progression free survival (PFS) and overall survival (OS), and toxicity profile of Capecitabine alone or in combination in the treatment of advanced and metastatic breast cancer patients.